Premium
LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
Author(s) -
Zinzani P. L.,
Caimi P. F.,
CarloStella C.,
Ai W.,
Alderuccio J. P.,
Ardeshna K. M.,
Hess B.,
Kahl B. S.,
Radford J.,
Solh M.,
Stathis A.,
Feingold J.,
Ungar D.,
Qin Y.,
He S.,
Hamadani M.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.89_2880
Subject(s) - medicine , refractory (planetary science) , clinical endpoint , adverse effect , diffuse large b cell lymphoma , phases of clinical research , surgery , lymphoma , oncology , gastroenterology , chemotherapy , clinical trial , astrobiology , physics